Migco Pharmaceuticals today announced the appointment of Matt Frevel as COO. He will assume operational management following the successful completion of Migco’s pre-clinical program.

[Rangiora, New Zealand] – [23 November 2009]—Migco Pharmaceuticals Ltd announced today the appointment of Elizabeth Hopkins as CEO.

[Rangiora, New Zealand] – [30 October 2009]—Results were presented today to the 19th World Congress of Neurology in Bangkok, Thailand indicating positive results with Migco’s MGX 008 amongst a group of migraine patients refractory to current pharmacologic treatments.

[Rangiora, New Zealand] – [26 October 2009]–Migco Pharmaceuticals announced today that has raised NZ$560,000 to continue developing its migraine prevention drug, codenamed MGX-008.

Press Release–Migco to Present at BioPartnering North America 8-10 February 2009, Vancouver Canada

Press Release Migco secures funding from experienced angel investor group Movac Ltd.

A clinical trial reported in Headache indicates that daily doses of antioxidants may reduce the frequency and severity of migraine headaches.